The Aducanumab Aftermath: The Industry

<p>How is the pharmaceutical industry reacting to the FDA’s surprising approval of a controversial Alzheimer’s drug, and what do they make of its $56,000 price tag?</p><p><br></p><p>This is the last episode in our weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.</p><p><br></p><p>Guest:</p><p><a href="https://timmermanreport.com/about-luke-timmerman/" rel="noopener noreferrer" target="_blank">Luke Timmerman</a>, Journalist/Founder, Timmerman Report</p><p><br></p><p>Explore the full series and additional resources:&nbsp;<a href="https://tradeoffs.org/aducanumab" rel="noopener noreferrer" target="_blank">https://tradeoffs.org/aducanumab</a></p><p><br></p><p>Read a transcript of this episode:&nbsp;<a href="https://tradeoffs.org/2021/06/25/the-aducanumab-aftermath-the-industry/" rel="noopener noreferrer" target="_blank">https://tradeoffs.org/2021/06/25/the-aducanumab-aftermath-the-industry/</a></p><p><br></p><p>Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: <a href="https://mailchi.mp/63a60bee39a5/tradeoffsnewsletter" rel="noopener noreferrer" target="_blank">bit.ly/tradeoffsnewsletter</a></p><p><br></p><p>Support this type of journalism today, with a gift: <a href="https://tradeoffs.org/donate" rel="noopener noreferrer" target="_blank">https://tradeoffs.org/donate</a></p><p><br></p><p>Follow us on Twitter:&nbsp;<a href="https://twitter.com/tradeoffspod" rel="noopener noreferrer" target="_blank">https://twitter.com/tradeoffspod</a></p> &#10;&nbsp;<br /><hr><p style='color: grey; font - size: 0.75em; '>See <a style='color: grey; ' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for privacy and opt-out information.</p>